Abstract
We conducted a 28-week, randomized, double-blind, parallel-group study of iguratimod in 376 Japanese patients with active rheumatoid arthritis to compare the efficacy and safety of the drug with those of placebo and salazosulfapyridine. In the American College of Rheumatology (ACR) 20 response rate, iguratimod was superior to placebo (53.8% versus 17.2%; Fisher's exact test, P < 0.001) and was not inferior to salazosulfapyridine (63.1% versus 57.7%, 95% confidence interval for the rate difference, −7.9% to 18.7%). Iguratimod began exhibiting its therapeutic effect within 8 weeks after the initiation of treatment and was effective even in patients who had a poor response to previous treatment with disease-modifying antirheumatic drugs. No statistically significant difference was noted in the incidence of adverse reactions between iguratimod and salazosulfapyridine. The study results suggest that iguratimod could become a new option for the treatment of rheumatoid arthritis.
Article PDF
Similar content being viewed by others
References
A Kawakami M Tsuboi S Urayama N Matsuoka S Yamasaki A Hida et al. (1999) ArticleTitleInhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells J Lab Clin Med 133 566–74 Occurrence Handle10360631 Occurrence Handle10.1016/S0022-2143(99)90186-5 Occurrence Handle1:CAS:528:DyaK1MXjvFOmu70%3D
M Kohno Y Aikawa Y Tsubouchi A Hashiramoto R Yamada Y Kawahito et al. (2001) ArticleTitleInhibitory effect of T-614 on tumor necrosis factor-α induced cytokine production and nuclear factor-κB activation in cultured human synovial cells J Rheumatol 28 2591–6 Occurrence Handle11764202 Occurrence Handle1:CAS:528:DC%2BD38Xht12iuw%3D%3D
Y Aikawa M Yamamoto T Yamamoto K Morimoto K Tanaka (2002) ArticleTitleAn anti-rheumatic agent T-614 inhibits NF-κB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with IκBα degradation Inflamm Res 51 188–94 Occurrence Handle12058956 Occurrence Handle10.1007/PL00000291 Occurrence Handle1:CAS:528:DC%2BD38XjtlWhtLc%3D
K Tanaka T Yamamoto Y Aikawa K Kizawa K Muramoto H Matsuno et al. (2003) ArticleTitleInhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted in SCID mice Rheumatology (Oxf) 42 1365–71 Occurrence Handle10.1093/rheumatology/keg381 Occurrence Handle1:CAS:528:DC%2BD3sXos1antbY%3D
K Tanaka T Shimotori S Makino Y Aikawa T Inaba C Yoshida et al. (1992) ArticleTitlePharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. 1st communication: antiinflammatory, analgesic and other related properties Arzneimittelforschung 42 935–44 Occurrence Handle1418059 Occurrence Handle1:CAS:528:DyaK38XlsVejs7c%3D
K Tanaka T Shimotori Y Taniguchi M Eguchi C Abe (1993) ArticleTitlePharmacological studies on T-614, a novel anti-inflammatory agent: effect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/l mice Int J Immunother 9 69–78 Occurrence Handle1:CAS:528:DyaK3sXmtFKqsLw%3D
JC Edwards G Cambridge (2001) ArticleTitleSustained improvement in rheumatoid arthritis following a protocol designed to delete B lymphocytes Rheumatology (Oxf) 40 201–11
S De Vita F Zaja S Sacco A Dde Candia R Fanin G Ferraccioli (2002) ArticleTitleEfficacy of selective B cell blockade in the treatment of rheumatoid arthritis; evidence for a pathogenetic role of B cells Arthritis Rheum 46 2029–33 Occurrence Handle12209504 Occurrence Handle10.1002/art.10467 Occurrence Handle1:CAS:528:DC%2BD38XmvFOqtLw%3D
FC Arnett SM Edworthy DA Bloch DJ McShane JF Fries NS Cooper et al. (1988) ArticleTitleThe American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315–24 Occurrence Handle3358796 Occurrence Handle1:STN:280:BieC1M3nt1Q%3D
DT Felson JJ Anderson M Boers C Bombardier D Furst C Goldsmith et al. (1995) ArticleTitleAmerican College of Rheumatology preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 727–35 Occurrence Handle7779114 Occurrence Handle1:STN:280:ByqB1MfgsFI%3D
T Pincus JA Summey SA Soraci SuffixJr KA Wallston NP Hummon (1983) ArticleTitleAssessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire Arthritis Rheum 26 1346–53 Occurrence Handle6639693 Occurrence Handle1:STN:280:BiuD2M3mt1Q%3D
JF Fries DA Bloch JT Sharp DJ McShane P Spitz GB Bluhm et al. (1986) ArticleTitleAssessment of radiologic progression in rheumatoid arthritis Arthritis Rheum 29 1–9 Occurrence Handle3947405 Occurrence Handle1:STN:280:BimC3s%2Fnslw%3D
Y Ichikawa T Shinozawa (1993) Variation of the estimation of radiologic progression in RA (in Japanese) BibInstitutionalEditorNameDrug Evaluation Committee of the Japan Rheumatism Foundation (Eds) Proceedings of the Symposium “New Developments in Drug Evaluation” Ikagakushuppansha Tokyo 23–9
K Mikanagi K Nishioka S Sugawara I Nagaya S Yamamoto Y Shiokawa et al. (1991) ArticleTitleA prospective long term study of enteric-coated salazosulfapyridine (PJ-306) in rheumatoid arthritis (in Japanese) The Clinical Report 25 1749–65
N Nishioka M Nobunaga A Sakuma (1991) ArticleTitleA double blind comparative study of 1 g/day, 2 g/day salazosulfapyridine and placebo in rheumatoid arthritis (in Japanese) Ryumachi 31 327–45 Occurrence Handle1683015 Occurrence Handle1:STN:280:By2D2Mrgtl0%3D
Physician's Desk Reference. 56th ed. New Jersey: Medical Economics; 2002. p. 1753
JS Smolen JR Kalden DL Scott B Rozman TK Kvien A Larsen et al. (1999) ArticleTitleEfficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial Lancet 353 259–66 Occurrence Handle9929017 Occurrence Handle10.1016/S0140-6736(98)09403-3 Occurrence Handle1:CAS:528:DyaK1MXhsF2lsr4%3D
DM van der Heijde PL Van Riel IH Nuver-Zwart FW Gribnau LB Van De Putte (1989) ArticleTitleEffects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis Lancet 333 1036–8 Occurrence Handle10.1016/S0140-6736(89)92442-2
InstitutionalAuthorNameThe Australian multicentre clinical trial group (1992) ArticleTitleSulfasalazine in early rheumatoid arthritis J Rheumatol 19 1672–7
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hara, M., Abe, T., Sugawara, S. et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 17, 1–9 (2007). https://doi.org/10.1007/s10165-006-0542-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10165-006-0542-y